Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
Nevertheless, Fiona McLaughlin, Chief Scientific Officer, pointed out that results so far are remarkably consistent across all the patients (or similar) so I think we can assume they are all responding. I don't think American would have licensed IND otherwise.
" It's not effective at identifying medium or low viral loads" (AffiDX)
Exactly why it was withdrawn and why all LFD's on sale should be too.....AS is maintaining.
"We therefore believe it is essential that similar Omicron sensitivity studies be performed on all SARS-CoV-2 antigen tests"
Nodding Do-Nut.....obfuscation. Of course it works:
RNS 10.1.22
"the AffiDX® antigen test is effective at identifying high viral loads of Omicron"
"We will therefore use the robustness of the Affimer® platform, and what we have learned about the SARS-CoV-2 virus, to generate the next generation antigen test "
"We therefore believe it is essential that similar Omicron sensitivity studies be performed on all SARS-CoV-2 antigen tests and the results communicated to ensure the public can have confidence in the results these tests generate."
The Telegraph reports:
"AstraZeneca shares rose after the pharmaceutical giant reported positive results from a late-stage trial of its prostate cancer drug.
The company said its Lynparza treatment combined with abiraterone delayed the risk of disease progression by more than eight months and allowed patients to maintain their quality of life.
Shares rose almost 5pc"
AZ is capitalised at £185 Billion so a 5% rise is about £9 Billion.
I think Avacta is a little bit under-valued.
https://www.telegraph.co.uk/business/2022/02/15/ftse-100-markets-live-news-oil-inflation-cryptocurrency-gas/?li_source=LI&li_medium=liftigniter-rhr
He did post yesterday.....18 Tweets:
https://twitter.com/MylesMcNulty/status/1491759660008980488
No 18: Myles McNulty
@MylesMcNulty
..most powerful chemotherapies in use - who have possibly experienced only 'asymptomatic' side-effects.
#AVCT's pre CISION is a platform tech.
The owner of it could ultimately go on to dominate - and in fact multiply - the size of the $60bn per annum chemotherapy market.
18/18
Needless to say I disagree and probably the dozens of skilled Wetherby employees do too. The basic requirement still exists...a highly accurate LFT. And the Americans may take a stronger view on the rubbish trying to pass off as accurate. Can Roche detect Omnicron....with rigour?
A little over a year ago £20M was committed to LFT products with Meduflow an example. Will Hughes and Kamani write that off? I'm sure they expect Avacta to fix this bloody strip and get the product back on track. It's far too soon to write off AffiDX.
You're not alone:
https://twitter.com/Ophidian18/status/1490626612920209408
Ophidian
@Ophidian18
·
1h
as #AVCT starts to become visible on the radar of big Pharma, the possibility of waking up to find the shares suspended one day grows........ wouldn't want to be Jupiter (or any other Gordon Geko wannabe shorter) on that day
4
24
Ophidian
@Ophidian18
·
57m
Also - just for consideration. the #AVCT share price on that day will be completely irrelevant. Deals like this (will be) value the Tech, the IP, the pipeline and the opportunity. The going rate is between $5Bn and $11Bn
Gruffell....the majority of funds do not follow AIM....too risky a market with low liquidity. My guess is Capital Access Group is here to get Avacta onto the main market or Nasdaq....and as quickly as possible. Before a Take Over. As it stands all this technology could be bought for a £1B or £4 a share.In my opinion.
I've assumed they recruited enough volunteers from the first three hospitals....with the others on standby for the next phase. The average patient isn't going to know AVA6000 from his backside so perhaps its not so easy to recruit. It's their life on the line.